watching it as well - summary of session 3 (MSCs for patients...

watching it as well - summary of session 3 (MSCs for patients with COVID-19)

Josh Hare - MSCs for COVID under EAP
14 patients (9 on ECMO) - 78% survival vs 55% in control group), suggested function of MSCs for COVID beyond just the lungs (heart mentioned)

Joan Kurtzberg
Looking at MIS-C using MSCs (not Mesoblast cells) - no data as yet but linked the mesoblast data demonstrating reduction of inflammation, safety over 10 yrs across 4000 doses delivered to kids (infants to 10) as a contributing factor as to why she thinks it will work. Phase 1 will be 4 doses @ 2millions cells/kg

Wenchun Qu - meta analysis - 5 comparative studies with control/treatment groups (179 patients total). 4 studies showed decreased mortality, 1 increased. Overall mortality was 25% for treated cf 43% controls ie 75% survival vs 57% survival)

From the data - Hare, Qu and MSB survivals are comparable (78%, 75% and 83% respectively) - 'control' survivals were similar (55%, 57% and IIRC, we are expecting around 50% survival for the current MSB phase 3?)